Loading...
•
Mar 31, 2020
Cue Biopharma Q1 2020 Earnings Report
Cue Biopharma reported first quarter 2020 results and provided updates on the CUE-101 Phase 1 dose escalation study and recent business highlights.
Key Takeaways
Cue Biopharma reported collaboration revenue of $0.9 million for the first quarter of 2020. Research and development expenses were $9.9 million, and general and administrative expenses were $3.9 million. The company's net loss for the quarter was $12.818 million, or $0.48 per share.
Collaboration revenue increased to $0.9 million from $0.4 million year-over-year.
Research and development expenses increased to $9.9 million due to clinical trial costs and manufacturing of CUE-101.
General and administrative expenses increased to $3.9 million due to stock-based compensation and legal/accounting fees.
Extended cash runway through an ATM equity offering sales agreement for aggregate proceeds of $34.3 million.
Cue Biopharma
Cue Biopharma
Cue Biopharma Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The press release does not contain forward guidance. Therefore, this field is empty.